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Abstract
Hepatocellular carcinomas are aggressive tumors with a high dissemi-
nation power. An early diagnosis of these tumors is of great impor-
tance in order to offer the possibility of curative treatment. For an early
diagnosis, abdominal ultrasound and serum alpha-fetoprotein deter-
minations at 6-month intervals are suggested for all patients with
cirrhosis of the liver, since this disease is considered to be the main risk
factor for the development of the neoplasia. Helicoidal computed
tomography, magnetic resonance and/or hepatic arteriography are
suggested for diagnostic confirmation and tumor staging. The need to
obtain a fragment of the focal lesion for cytology and/or histology for
a diagnosis of hepatocellular carcinoma depends on the inability of
imaging methods to diagnose the lesion. Several classifications are
currently available for tumor staging in order to determine patient
prognosis. All take into consideration not only the stage of the tumor
but also the degree of hepatocellular dysfunction, which is known to
be the main factor related to patient survival. Classifications, however,
fail to correlate treatment with prognosis and cannot suggest the ideal
treatment for each tumor stage. The Barcelona Classification (BCLC)
attempts to correlate tumor stage with treatment but requires prospec-
tive studies for validation. For single tumors smaller than 5 cm or up
to three nodules smaller than 3 cm, surgical resection, liver transplan-
tation and percutaneous treatment may offer good anti-tumoral re-
sults, as well as improved patient survival. Embolization or
chemoembolization are therapeutic alternatives for patients who do
not benefit from curative therapies.
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Introduction
Hepatocellular carcinoma (HCC) is the
most frequent primary solid tumor of the
liver. Its aggressiveness and extensive dis-
semination lead to a poor patient prognosis.
HCC is estimated to account for 5% of all
malignant neoplasias (1). Its prevalence is
considered to be high (>20 cases/100,000
inhabitants/year) in the far East and Africa,
medium (5 to 20 cases/100,000 inhabitants/
year) in Europe, and low (<5 cases/100,000
inhabitants/year) in South America. In Bra-
zil, its prevalence is considered to be low,
despite geographic variations (2).
Cirrhosis of the liver, regardless of etiol-
ogy, is considered to be the main risk factor for
the onset of HCC. In Africa and in South Asia,
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hepatitis B is the main cause of hepatic dis-
ease. In these regions, HCC may develop
among young patients, even when they do not
have cirrhosis of the liver because infection
with the hepatitis B virus occurs during deliv-
ery or soon after birth, with the prolonged
period of infection being the major determi-
nant of the onset of HCC in these patients. In
the Western World and in Japan, hepatitis C
virus is the main factor related to the presence
of cirrhosis of the liver in patients with HCC.
In a survey conducted by the Brazilian Society
of Hepatology in Brazil in 1995 cirrhosis of
the liver was present in 71% of patients with
HCC, with the cause of liver disease being
hepatitis B in 39% of cases, hepatitis C in 27%
and alcoholism in 37%. In our patient series,
hepatitis C virus (43%) and alcoholism (38%)
are the major causes of liver cirrhosis in pa-
tients with HCC (3).
Cirrhosis of the liver is present in 60 to
100% of patients with HCC (4,5) depending
on regional variations. Among our patients
with HCC, 90% have cirrhosis of the liver (3).
With the identification of cirrhosis of the
liver as the main risk factor for the develop-
ment of HCC, and in view of the high aggres-
siveness of this type of neoplasia when diag-
nosed in advanced stages, periodic follow-
up is necessary for an early diagnosis of the
tumor.
HCC is a tumor that satisfies the require-
ments of neoplasias for which screening is
justified. There is a well-defined risk group
(cirrhosis of the liver), there are effective,
noninvasive and low cost diagnostic tech-
niques (ultrasound, US, and alpha-1 fetopro-
tein, AFP), and curative therapeutic tech-
niques are available which can increase pa-
tient survival (resection, liver transplanta-
tion and percutaneous treatment).
Diagnosis
An early diagnosis of HCC is required
for the institution of treatments considered
to be curative. On this basis, screening of
each patient with cirrhosis of the liver re-
gardless of etiology is of primordial impor-
tance for the detection of tumors in the initial
stages of development. It has been suggested
that monitoring should be performed by US
and by measurements of serum AFP at 6-
month interval. The option for a 6-month
interval is based on the mean time for tumor
duplication, which is about 6.5 months and
may range from 1 to 20 months (6,7). Shorter
intervals (3 to 4 months) or the use of other
imaging methods such as helicoidal com-
puted tomography have been suggested for
HCC screening in patients considered to be
at high risk. However, the definition of what
should be considered a high risk varies among
investigators and also among the popula-
tions studied. A comparison of the different
schedules (reduced intervals between ex-
ams) or the use of other imaging techniques
is lacking in the literature.
However, only patients who would benefit
from curative treatment should be submitted
to screening. On this basis, in patients with
cirrhosis of the liver classified as Child-Pugh
C with no indication for liver transplantation,
monitoring with US and AFP will be of no
benefit in terms of patient survival.
Ultrasound
US is considered to be the technique of
choice for the diagnosis of focal hepatic
lesions (8), permitting the detection of tu-
mors of small size (1 cm) still in the early
phase of development and thus being justi-
fied for the screening of HCC in patients
with cirrhosis of the liver (8,9). The ultraso-
nographic characteristics of HCC depend on
nodule size. Small nodules of less than 3 cm
are frequently hypoechogenic. As they in-
crease in size, they start to acquire isoecho-
genic characteristics with a peripheral halo
or hyperechogenic or heterogeneous charac-
teristics due to the neoformation of blood
vessels and intratumoral necrosis. Other pos-
sible findings are lateral shadows, a poste-
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rior reinforcement and a perilesional halo
that corresponds to the presence of a peritu-
moral fibrous capsule consequent to the com-
pression of the adjacent hepatic parenchyma
(8). US can also be used to assess the perme-
ability of vascular structures and the exist-
ence of hilar adenopathies suggestive of tu-
moral extension.
The sensitivity of US for the detection of
HCC is directly related to tumor size. Its
diagnostic sensitivity for tumors smaller than
1 cm is about 42% (10,11), reaching 95% for
tumors of larger size (12).
The combination of Doppler with US can
be useful for the identification of portal
thrombosis in patients with HCC, with 89 to
92% sensitivity and 100% specificity in the
identification of tumor thrombosis (13). The
presence of a hepatofugal pulsatile flow in-
side the thrombus is suggestive of vascular
invasion (14). Hepatic arteriography for the
identification of portal thrombosis can be
avoided when US-Doppler reveals perme-
ability of the portal system (13). In patients
with tumors submitted to alcoholization,
chemical thrombosis can be differentiated
from tumoral thrombosis by means of US-
Doppler based on the presence of blood flow
in the thrombus. The presence of a pulsatile
thrombus rules out the possibility of benign
thrombosis (by alcohol), confirming the pres-
ence of tumoral invasion of portal vessels. In
cases in which doubts persist about the cause
of portal thrombosis, fine needle aspirative
puncture can be used, a highly sensitive
procedure for the confirmation of tumoral
thrombosis which also involves low risks of
complications (14).
In addition to providing an imaging diag-
nosis, US can also be used to guide the
needle for aspirative puncture or for a biopsy
carried out to obtain a tissue fragment from
the tumor nodule (8).
Alpha-1 fetoprotein
Under physiological conditions, AFP is
synthesized by the embryonic liver, by cells
of the vitellin sac and by the fetal intestinal
tract. Patients with chronic liver disease,
especially those with a high degree of hepa-
tocyte regeneration, can express AFP in blood
in the absence of malignant neoplasia.
Measurement of serum AFP levels is not
useful for the early detection of HCC be-
cause, even though 80% of the patients with
HCC have serum AFP concentrations ex-
ceeding normal levels (10-20 ng/ml), pa-
tients with a high liver regenerative activity
may express higher than normal AFP values
without having HCC (8,15,16).
AFP serum levels above 400-500 ng/ml
are considered to be diagnostic of HCC in
cirrhotic patients with focal hepatic lesions
(8). However, only 1/3 of patients with HCC
have AFP levels higher than 100 ng/ml, with
levels above 400 ng/ml being quite infre-
quent in the presence of small tumors (<5
cm) (8).
Even though they do not reach levels
considered to be diagnostic (400-500 ng/
ml), progressively increasing AFP concen-
trations during screening are suggestive of a
diagnosis of HCC. These patients should be
submitted to helicoidal computed tomogra-
phy in order to rule out the diagnosis of a
tumor. The values and the time interval be-
tween AFP measurements needed for them
to be considered as “progressively increas-
ing AFP levels” have not yet been estab-
lished.
With the development of early detection
programs, an increase in the number of cases
with small tumors and normal AFP levels
(29%) has been observed (16). In our experi-
ence, 42% of patients with HCC present
serum AFP levels within normal limits (3).
At the time of tumor diagnosis, AFP seems
to be of prognostic value. This may be due to
the fact that well-differentiated tumors ex-
press less AFP and patients with normal AFP
have a lower incidence of tumoral vascular
invasion and tend to present better hepatic
function, which is known to be one of the
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major prognostic factors for these patients
(16-18).
Other tumor markers
Des-gamma carboxyprothrombin (DCP)
is another tumor marker used for the diagno-
sis of HCC. Its diagnostic efficacy has been
investigated by various groups, with contra-
dictory results. There are reports of the supe-
riority of DCP over AFP in the diagnosis of
HCC, especially in the Orient and in North
America. However, studies conducted in
Europe have not shown a better performance
of DCP compared to AFP. Racial and etio-
logical factors of liver disease may be re-
sponsible for the discrepant results. Despite
the contradictory results, the combination of
the two markers is suggested to increase the
diagnostic efficacy. Studies on large patient
series and on diverse ethnic populations are
needed to clarify the real role of DCP in the
diagnosis of HCC.
Other markers such as interleukin-2, uri-
nary tumor growth factor-ß1 and MAGE-4
protein receptors have also been used in
research to aid the diagnosis of HCC but
their clinical applicability requires scientific
confirmation.
In the presence of a diagnostic suspicion
by US and/or AFP, the patient should be
further investigated by helicoidal computed
tomography (CT) and/or magnetic resonance
(MR) and, in selected cases, by hepatic arte-
riography, in order to confirm the suspected
diagnosis and determine the stage of the
tumor.
Helicoidal computed tomography
After the suspicion of HCC by US in a
patient with cirrhosis of the liver, the use of
CT is suggested. The sensitivity of CT for
the diagnosis of HCC is similar to that of US.
Its diagnostic efficacy depends on technical
factors, mainly the injection of contrast, and
on factors inherent to the tumor, the most
important of which are tumor size and vas-
cularization. CT should be performed by the
spiral (or helicoidal) technique with intrave-
nous injection of contrast and images should
be obtained in the basal, arterial, portal, and
equilibrium phases. The main characteristic
of HCC detected by CT is the early uptake of
contrast in the arterial phase of the exam.
Due to the hypovascularization of small-
sized tumors, the diagnostic efficacy of CT
is reduced in tumors measuring less than 2
cm (19,20). A second phase after the intrave-
nous contrast increases the diagnostic sensi-
tivity when associated with the arterial phase,
when the HCC is found to be iso- or hypo-
dense (20). When images and intravenous
contrast are associated, a greater capacity to
detect HCC is achieved.
The use of standard CT causes technical
difficulties such as respiratory artifacts and
difficulty in capturing images during the ar-
terial phase of the contrast dye. To obviate
these technical difficulties, the helicoidal
(spiral) technique has been used which, due
to the rapid image acquisition, permits the
capture of sections of the entire liver during
a single moment of apnea. This technique
increases by about 15% the diagnostic sensi-
tivity for the detection of hepatic tumors
smaller than 2 cm compared to standard CT.
CT also reveals the presence of tumor in-
volvement of lymph nodes, vascular inva-
sion and extrahepatic involvement with high
sensitivity, specificity and diagnostic accu-
racy.
Intra-arterial injection of lipiodol fol-
lowed by CT (CT-lipiodol) presents low di-
agnostic sensitivity (37%) which is not higher
than that of helicoidal CT, in addition to
being an invasive method (10). Thus, the
CT-lipiodol technique has not been routinely
used for the diagnosis of HCC.
Magnetic resonance
MR has been used to obtain a better
characterization of hepatic lesions sugges-
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tive of HCC and also for their differentiation
from benign lesions (21). HCC is better evalu-
ated in potentiated sequences in T2, where it
frequently appears to be hyperintense (22,23).
In potentiated sequences in T1, because of
the larger amount of water inside them, which
increases the relaxation time, HCC are found
to be hypointense. The hyperintensity in T1
may be attributed to the presence of steato-
sis, to the formation of light cells and to
intratumoral copper accumulation. Intrave-
nous injection of paramagnetic contrast (ga-
dolinium-DTPA) is also used to better char-
acterize the lesions. As observed with CT,
HCC appears as a hyperdense image with
contrast uptake. The sensitivity of MR de-
pends on tumor size. In tumors larger than 2
cm the level of detection is about 95%. How-
ever, in tumors smaller than 2 cm this level is
reduced to 30% (22). The diagnostic effi-
cacy of MR for the detection of HCC seems
to be similar to or even lower than that of CT.
However, this imaging technique is very use-
ful for the demonstration of the internal ar-
chitecture of the tumor, of the tumoral mar-
gins, of the presence of a peritumoral cap-
sule, and of intrahepatic vascular invasion
(22).
One of the major useful properties of MR
is the differential diagnosis from hepatic
hemangioma (8). Because of the lack of
anatomical limitation, MR and CT are supe-
rior to US for the diagnosis of tumors close
to the lung and of isoechogenic lesions (15).
Hepatic arteriography
The diagnostic efficacy of hepatic arteri-
ography (HA) depends on tumor size and on
the extent of tumor vascularization (19).
Small tumors tend to be well differentiated
and consequently present low vasculariza-
tion, thus being difficult to detect by this
technique (24). For tumors smaller than 5
cm, HA has 82 to 93% diagnostic sensitivity,
73% specificity and 89% diagnostic accu-
racy, with these values being even more
reduced when the tumors are smaller than 2
cm (24,25).
Only in selected cases is it possible to use
laparoscopy for the diagnosis of HCC, since
this technique only analyzes the presence of
superficial lesions.
The diagnostic accuracy of imaging tech-
niques for the detection of HCC depends on
the characteristics of the tumor and on the
experience of each study group. In our expe-
rience (12,26), the ability to diagnose HCC
is 84% for US, 79% for CT, 77% for MR,
and 64% for HA. Thus, because of its low
cost and availability, we believe that US
continues to be the exam of choice for an
early diagnosis of HCC, being useful for the
monitoring of cirrhotic patients. However,
the experience and awareness of the opera-
tor is of primordial importance during the
execution of the exam.
Cytology and/or histology
Cytologic and/or histopathologic exami-
nation of the suspected lesion can also be
used for the diagnosis of HCC. The material
to be used for cytology is obtained by fine
needle aspirative biopsy (FNAB). This is a
safe technique with minimal risks of compli-
cations due to the procedure, which provides
adequate material when performed by trained
personnel. Its diagnostic accuracy may vary
from 60 to 90% (8,27) depending on the size
of the lesion, on the examiner and on the
diameter of the puncturing needle. The speci-
ficity and positive predictive value of this
technique are higher than 90%, reaching
100% in our experience (27).
Histopathological examination is the main
method for a sure diagnosis of HCC. A non-
tumoral liver biopsy is important to rule out
or to confirm the presence of liver cirrhosis,
since the presence of cirrhosis may contrain-
dicate surgical treatment. The two pathology
techniques can be used for the diagnosis of
HCC and their combination can increase the
diagnostic accuracy (27). To prevent com-
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plications, the nodule should always be punc-
tured through the non-tumoral liver, which
will serve as a “buffer” preventing bleeding.
Diagnostic criteria
In a recent publication, the European
Association for the Study of the Liver (EASL)
(28) proposed guidelines and criteria for the
diagnosis of HCC in cirrhotic patients (Fig-
ure 1). The presence of a nodule larger than
2 cm with hypervascular characteristics de-
tected by at least two imaging techniques
confirms the presence of HCC, with no need
for cyto-histopathological confirmation.
FNAB and/or a biopsy of the suspected le-
sion with a cutting needle are suggested for
cirrhotic patients with nodules smaller than
2 cm, since in about 50% of cases the diag-
nosis of HCC cannot be confirmed by imag-
ing methods (1).
The diagnostic criteria (28) are cytological
and/or histological criteria, or noninvasive cri-
teria, which include 1) radiologic criterion:
two coinciding imaging techniques demon-
strating a focal hepatic lesion >2 cm with
arterial hypervascularization, or 2) combined
criteria: an imaging technique associated with
increased serum AFP levels, a focal lesion >2
cm with arterial hypervascularization, and se-
rum AFP levels >400 ng/ml.
The imaging techniques to be evaluated
are US, CT, MR, and HA. However, the
technology for the execution of all imaging
exams suggested by the EASL is not avail-
able at all hospital centers. Similarly, the
curative therapies also require properly
trained specialized teams that are not avail-
able at all medical services. This fact leads to
two observations: 1) screening with US and
AFP should be performed only in cases in
which the medical team can offer curative
therapies (surgical resection, liver transplan-
tation and percutaneous treatment); 2) the
lack of access to helicoidal CT, MR and HA
does not exclude the possibility of diagnos-
ing HCC. In this situation we believe that
FNAB and/or a biopsy of the lesions should
be obtained for a sure diagnosis regardless
of tumor size, as long as the patients can be
treated with available techniques.
Staging
The main objective of tumor staging is to
determine the prognosis of the disease and to
Cirrhotic patients* (US/AFP 6/6 months)
Hepatic nodule Absence of nodules
>1 cm <1 cm Elevated AFP** Normal AFP
<2 cm >2 cm US 3/3 months Helicoidal CT
Cyto/Histology AFP ≥400 ng/ml
CT/MR/HA
Without HCC
US/AFP 6/6 monthsHepatocellular carcinoma***
Figure 1. Diagnosis of hepato-
cellular carcinoma according to
the Barcelona-2000 Conference
of the European Association for
the Study of the Liver (EASL)
(28). *Patients who can be sub-
mitted to curative treatment if
an HCC is diagnosed; **Unde-
fined AFP level; ***Confirma-
tion by pathology or by a nonin-
vasive criterion. AFP = alpha-1
fetoprotein; CT = computed to-
mography; HA = hepatic arteri-
ography; HCC = hepatocellular
carcinoma; MR = magnetic reso-
nance; US = ultrasound.
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Table 2. Barcelona Clinic Liver Cancer (BCLC) Group classification of hepatocellular carcinomas (29).
Stage PST Tumor stage Okuda Portal hypertension Total bilirubin Child-Pugh
A
A1 0 Single I No Normal
A2 0 Single I Yes Normal
A3 0 Single I Yes Altered
A4 0 3 <3 cm I-II A-B
B 0 >5 cm I-II A-B
Multinodular
C 1-2 Vascular invasion  I-II A-B
and/or metastasis
D 3-4 Any stage III C
PST = Performance status test.
establish the best therapeutic method for the
patient. Several factors should be analyzed
in cirrhotic patients with HCC. Prognosis
and treatment mainly depend on the degree
of hepatic dysfunction, tumor stage and gen-
eral patient condition. It should be kept in
mind that most patients with HCC have as-
sociated cirrhosis of the liver, this being a
factor frequently as important or even more
important than tumor stage.
Various classifications have been adopted
to stage HCC. The first was developed in
1985 by Okuda et al. (5) (Table 1) in a study
on 850 patients with HCC using data con-
cerning tumor size (> or < than 50% of the
liver size), serum bilirubin levels (> ou <3
mg/dl), serum albumin levels (> or <3 g/dl),
and the presence of ascites, classified HCC
into three stages. The mean survival rate for
patients with stages I, II and III was 11.5, 3
and 0.9 months, respectively, without con-
sidering the treatment variable. When the
patients submitted to surgical resection of
the tumor were analyzed, survival reached
25.6 months for patients with Okuda stage I.
Several other prognostic classifications
of HCC are currently being used:
Barcelona Clinic Liver Cancer (BCLC)
Group (29) (Table 2). This classification
takes into consideration hepatic function,
portal hypertension, bilirubins, symptoms
related to the tumor, tumor morphology, pres-
ence of distant metastases, or vascular inva-
sion. This is the only classification that cor-
relates prognostic data with therapeutic pos-
sibilities.
TNM classification (30) (Table 3). This
classification considers the size and number
of nodules, vascular invasion, and bilobar
involvement. Hepatic function is not consid-
ered as a factor in staging, although it is an
important factor for the prognosis of these
patients. Evaluation of this classification in
patients submitted to liver transplantation
did not show benefits in prognostic terms for
patients with HCC (30). The inclusion of the
hepatic fibrosis factor in staging by TNM
has been recently suggested.
French classification (31) (Table 4). This
classification includes as prognostic factors
Table 1. Okuda classification of hepatocellular
carcinomas (5).
Negative Positive
Tumor size <50% of liver >50% of liver
Ascites Absent Present
Serum albumin >3 g/dl <3 g/dl
Bilirubin <3 mg/dl >3 mg/dl
Okuda I: No positive factor; Okuda II: 1 or 2
positive factors; Okuda III: 3 or 4 positive factors.
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Table 4. French classification of hepatocellular carcinomas (31).
0 1 2 3
Karnofsky index (%) ≥80 <80
Bilirubin (µmol/l) <50 ≤50
Alkaline phosphatase (MNL) <2 ≥2
Alpha-1 fetoprotein (µg/l) <35 ≥35
Portal obstruction (US) No Yes
Karnofsky index >80% = complete patient autonomy; MNL = maximum normal limit;
US = ultrasound. Group A (low risk): 0 point; group B (intermediate risk): 1-5 points;
group C (high risk): ≥6 points.
intermediate risk (score 1 to 5), and 7 and 3%
for high risk patients (score ≥6), respec-
tively. It should be pointed out that this
classification was based on the analysis of
patients (47%) submitted to some type of
treatment. In addition, mean patient survival
was only 4.3 months, suggesting selection of
patients with an advanced stage of the disease.
Chinese University Prognostic Index (32)
(Table 5). This index includes the TNM
classification associated with serum levels
of bilirubin, alkaline phosphatase, AFP, pres-
ence of ascites, and absence of clinical symp-
toms at the time of diagnosis. The score
ranges from -7 to 12. The mean survival is 10
months for low risk patients (score ≤1), 3.7
months for patients at intermediate risk (score
from 2 to 7), and 1.4 months for high risk
patients (score ≥8). It should be pointed out
that the patients analyzed in the cited study
were Chinese, most of them (79%) with
cirrhosis of the liver due to hepatitis B virus.
Of the patients evaluated, 41.6% were sub-
mitted to some antitumoral treatment which
might have interfered with data assessment.
The low mean survival for these patients (19
weeks) may also suggest the selection of
patients with advanced tumors.
Cancer of the Liver Italian Program (17)
(Table 6). This program includes hepatic
function, tumor morphology, presence of
thrombosis of the portal vein, and serum
AFP levels. It should also be pointed out that
part of the patients were submitted to either
regional (57%) or systemic (18%) treatment,
a fact that may change the data of this prog-
nostic system. The tumors of the patients are
divided into 7 stages (0 to 6). Mean survival
is 35, 8 and 3 months for stages 0, 2 and 4-6,
respectively (18).
As is the case for diagnosis, population
differences also influence the prognostic
models. In contrast to other types of tumors
in which the neoplasia is responsible for
mortality, in HCC, cirrhosis of the liver is
the main factor related to patient survival. In
general, hepatocellular function is consid-
the Karnofsky index, serum bilirubin levels,
AFP, alkaline phosphatase, and the presence
of portal thrombosis detected by US. The
score ranges from 0 to 11. The 1- and 2-year
survival rate was 72 and 51% for low risk
patients (score 0), 34 and 17% for patients of
Table 3. TNM classification of hepatocellular carcinomas (30).
Classification Definition
T1 Solitary tumor ≤2 cm in the widest diameter without vascular invasion.
T2 Solitary tumor ≤2 cm in the widest diameter with vascular invasion;
or multiple tumors limited to one lobe, none of them >2 cm in the
widest diameter, without vascular invasion;
or solitary tumor >2 cm in the widest diameter, without vascular
invasion.
T3 Solitary tumor >2 cm in the widest diameter with vascular invasion;
or multiple tumors limited to one lobe, none of them >2 cm in the
widest diameter, with vascular invasion;
or multiple tumors limited to one lobe, some of them >2 cm in the
widest diameter, with or without vascular invasion.
T4 Multiple tumors in more than one lobe;
or tumor(s) invading a large portal branch or one or more suprahepatic
veins. Solitary tumor >2 cm in the widest diameter with vascular
invasion.
Stage of TNM classification
I T1 / N0 / M0
II T2 / N0 / M0
III A T3 / N0 / M0
III B T1 / N1 / M0
T2 / N1 / M0
T3 / N1 / M0
IV A T4 / any N / M0
IV B any T / any N / M1
 T = tumor; N = nodes; M = metastasis; N0 = without regional lymph nodes; N1 = with
regional lymph nodes; M0 = without distant metastasis; M1 = with distant metastasis.
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ered to represent one of the major variables
related to patient survival. In addition, he-
patic dysfunction determines the type and
efficacy of the treatment proposed.
Another factor just as important is the
presence of neoplastic vascular invasion.
Four of the classifications presented earlier
consider the presence of vascular invasion to
be a factor related to survival, indicating
tumor dissemination. However, in most cases,
vascular invasion is diagnosed only during
histopathological analysis, i.e., after the ap-
plication of therapeutic procedures such as
resection and liver transplantation. Unfortu-
nately, currently available imaging methods
are not sufficient for the diagnosis of tu-
moral thrombosis of small hepatic vessels.
Serum AFP levels are also considered to
be of prognostic value in three classifica-
tions. Due to the low general survival rates
of the patients evaluated by these classifica-
tions, it is possible that selection of patients
with advanced tumors occurred, since early
HCC tend not to express high AFP levels.
One of the great benefits of tumor classi-
fication, in addition to providing an estimate
of survival, is the selection of patients who
can be submitted to treatment. The treat-
ments currently used for HCC have shown
an effect on patient survival, especially sur-
gical and percutaneous therapies. However,
none of the classifications available consid-
ers this variable (treatment). On this basis,
the new classifications should evaluate the
treatment options as a prognostic factor and
correlate the tumor stages with the form of
treatment to be adopted. The only classifica-
tion that tries to correlate tumor stage with
treatment is that of the Barcelona Group
(BCLC). However, this classification still
awaits prospective validation. Regional mul-
ticenter studies on large patient series are
needed to clarify the best time and types of
treatment for each patient with HCC.
The main sites of HCC metastases are the
adrenal glands, the bones and the lungs.
Thus, it is imperative to perform bone scin-
Table 6. Cancer of the Liver Italian Program (CLIP)
classification of hepatocellular carcinomas (17).
Variable Points
Child-Pugh
A 0
B 1
C 2
Tumor morphology
Uninodular and extension <50% 0
Multinodular and extension ≤50% 1
Diffuse (massive) or extension >50% 2
Alpha-1 fetoprotein
<400 0
≥400 1
Thrombosis of the portal vein
No 0
Yes 1
CLIP classification: 0 to 6 points.
tigraphy and chest and abdomen tomogra-
phy to rule out tumor dissemination. Al-
though uncommon, brain metastasis may
occur (33). For patients who benefit from
radical or curative treatment, mainly liver
transplantation, we believe that skull tomog-
raphy should be performed routinely to ex-
Table 5. Chinese University Prognostic Index
(CUPI) classification of hepatocellular carcinomas
(32).
Variable Score
TNM classification
I and II -3
III A and III B -1
IV A and IV B 0
Asymptomatic at diagnosis -4
Ascites 3
AFP ≥500 ng/ml 2
Bilirubin (µmol/l)
<34 0
34-51 3
>51 4
Alkaline phosphatase ≥200 IU/l 3
Score ≤1: low risk; score 2-7: intermediate risk;
score ≥8: high risk. Risk of death within 3 months:
>70% (high risk); 30 to 70% (intermediate risk);
<30% (low risk).  AFP = alpha-1 fetoprotein. For
stages of the TNM classification, see legend to
Table 3.
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clude the presence of brain metastases.
Treatment
The small number of patients with the
same tumor stage impairs the execution of
randomized and controlled studies, with a
consequent difficulty in reaching a reliable
conclusion about the best treatment for HCC.
However, the consensus is that for effective
treatment the tumor must be detected in the
early phases of development. A tumor is
considered to be in an early stage when its
size does not exceed 2 cm. However, single
tumors of less than 5 cm or up to three
nodules, none of which exceeds 3 cm, are
considered to be candidates for curative treat-
ment. With follow-up programs for cirrhotic
patients by US and AFP, the number of
patients that can be submitted to curative
treatment has increased. Tumors diagnosed
in advanced phases, with vascular invasion,
multinodular, and with distant metastases
cannot be treated with the objective of im-
proving patient survival. However, despite
the programs of early detection of HCC,
only 1/3 of patients with HCC will benefit
from treatment considered to be curative. In
our experience, we were able to perform
radical treatment in 25% of patients with
HCC (3).
The fibrolamellar variant of HCC is more
common among non-cirrhotic young patients.
Due to the slow evolution and low metasta-
sis rates of this tumor, the treatment of choice
is surgical resection even for tumors of large
volume since the hepatic functional reserve
needed for the procedure is maintained and
the remaining liver in most cases is normal.
When the tumor is not resectable, liver trans-
plantation may be indicated. However, most
HCC are not of the fibrolamellar variant and
occur in the presence of cirrhosis, with con-
sequent impairment of treatment. Thus, we
shall comment on the treatment of HCC in
patients with cirrhosis.
Surgical treatments (surgical resection
and liver transplantation) and percutaneous
treatment (alcoholization, radiofrequency and
microwaves) are considered to be curative or
radical. A 74% 5-year survival rate can be
reached by patients submitted to liver trans-
plantation (Table 7).
Surgical resection
Surgical resection is considered to be the
option of choice for the treatment of patients
with HCC. However, due to the frequent
occurrence of postoperative hepatic decom-
pensation, this treatment modality should be
indicated only for patients with preserved
Table 7. Survival after radical treatment of hepatocellular carcinoma.
N 1 year 2 years 5 years
Surgical resection
Fong et al.,1999 (35) 100 83 - 42
<5 cm - - 57 -
Llovet et al.,1999 (36)
No PH and TB NL 35 91 87 74
PH and TB NL 15 93 59 50
PH and TB >1 27 74 35 25
Arii et al.,2000 (34)
Stage 1 <2 cm 1318 - 88 71
Stage 1 2-5 cm 2722 - - 58
Yamamoto et al.,2001 (37) 58 97 84 61
Liver transplantation
Figueras et al.,1997 (41) 38 82 75 63
França,1997 (12)/Llovet et al.,1998 (26) 58 84 74 74
Jonas et al.,2001 (42) 120 90 - 71
Yao et al.,2001 (44)
≤pT2 46 91 - 72
Alcoholization
Livraghi et al.,1995 (50)
<5 cm
Child A 293 98 79 47
Child B 149 93 63 29
Child C 20 64 0 0
Arii et al.,2000 (34)
Stage 1 <2 cm 767 - 81 54
Stage 1 2-5 cm 587 - - 39
Yamamoto et al.,2001 (37) 39 100 82 59
Radiofrequency
Buscarini et al.,2001 (52)
≤3.5 cm 88 89 62 33
NL = normal value; PH = portal hypertension; TB = total bilirubin.
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hepatic function. Non-judicious patient se-
lection for surgical resection may not lead to
increased survival when surgical treatment
is compared to the natural history of HCC or
even to other less invasive therapies (34-37).
The Child-Pugh classification and indocya-
nine green clearance have been used to as-
sess the extent of liver function impairment
before the indication of the surgical proce-
dure. The presence of portal hypertension
represented by the portal pressure gradient
(difference between occluded and free he-
patic venous pressure) ≥10 mmHg has been
used as one of the main factors predictive of
hepatic decompensation after surgical resec-
tion (36). This suggests that resection should
be indicated for patients without portal hy-
pertension. When it is not possible to meas-
ure portal pressure by the angiographic route,
an invasive method which is not available at
most services in Brazil, other signs of portal
hypertension can be determined, such as
splenomegaly, presence of esophageal va-
rices upon upper gastrointestinal endoscopy,
and a platelet count of less than 100,000/
mm3, and used as criteria to rule out resec-
tion (36).
A single tumor measuring less than 5 cm
in patients with preserved hepatic function
and in sufficiently good clinical conditions
to withstand the procedure is the criterion
most often used to indicate resection. Nod-
ules larger than 5 cm present a higher prob-
ability of invasion of the tumor capsule, with
the presence of satellite nodules indicating
local tumor dissemination.
Only about 10% of patients have these
tumoral characteristics, with a consequent
infrequent indication of surgical resection
(38). Tumor localization, especially in a
perihilar situation, may be a criterion for
contraindication of resection regardless of
the characteristics of the tumor. Intraopera-
tive US should be routinely used both to
define the safety margins and to exclude
other lesions not visualized by preoperative
imaging techniques (39).
The survival rate after resection can reach
97% for the 1st year and 74% for the 2nd,
depending on residual hepatic reserve and
tumor staging (39). When possible, conser-
vative surgery should be performed, such as
segmentectomy or sub-segmentectomy which
will preserve a functioning liver mass. Tu-
mor recurrence is observed in about 12, 60
and 70% of patients after 1, 3 and 5 years,
respectively (36,38) and is related to the
presence of satellite nodules and tumor dif-
ferentiation (40). Recurrence may be local
or may consist of the appearance of meta-
chronic tumors since the cirrhotic liver, es-
pecially when involved by extensive inflam-
matory activity, continues to be a risk factor.
Tumor size (>5 cm), vascular invasion, the
presence of satellite nodules, bilobar involve-
ment, and the involvement of regional lymph
nodes are considered to be factors related to
tumor recurrence (36,38).
Liver transplantation
Liver transplantation is the treatment of
choice in cases of HCC limited to the liver
that cannot be submitted to surgical resec-
tion due to poor hepatic function or to tech-
nical impossibility. Liver transplantation not
only eliminates the neoplasia, but can also
cure the base liver disease. Some authors
adopt post-resection tumor recurrence as an
indication for liver transplantation. Others
adopt liver transplantation as the treatment
of choice before resection. When strict se-
lection criteria are used, such as a single,
small tumor (<5 cm) without satellite nod-
ules, without vascular invasion, without in-
vasion of regional lymph nodes, without dis-
tant metastases, and without an indication
for resection, a satisfactory survival can be
obtained (12,26,41-44). In our experience
(12,26), with single tumors smaller than 5
cm, the possibilities of survival reach 84, 74
and 74% in the 1st, 2nd and 5th years after
liver transplantation, with a rate of tumor
recurrence of only 3.5%. These survival rates
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are similar to those observed for liver trans-
plantation in patients without neoplasias
(41,45). Thus, the ideal candidate for liver
transplantation is a patient with a single HCC
smaller than 5 cm or with up to 3 nodules,
none of them larger than 3 cm, without signs
of neoplastic invasion of the portal system or
of distant metastases.
Despite its advantages, the procedure also
involves some disadvantages. The lack of
donors with a consequent increase in the
time on the waiting list, the high cost of the
procedure, the possibility of tumor recur-
rence, the frequent postoperative infections,
the high rates of perioperative morbidity,
and the quality of postoperative life are as-
pects that should be taken into account at the
time when the decision for an indication of
liver transplantation is made.
Pre-liver transplantation co-adjuvant
treatment in order to prevent tumor progres-
sion until the time for the surgical procedure
has been adopted at some transplant centers
where the time on the waiting list is more
than 6 months. The real efficacy of these
treatments for patient prognosis is still a
matter of controversy. Some groups use arte-
rial embolization with or without chemo-
therapy as co-adjuvant pre-liver transplanta-
tion treatment and localized chemotherapy
post-liver transplantation (46). The combi-
nation of techniques, such as embolization
and alcoholization, has demonstrated a satis-
factory antitumoral effect and may be useful
for co-adjuvant treatment before liver trans-
plantation (47).
Strategies to increase the number of do-
nors are of great importance. “Domino” and
split liver transplants are options used to
increase the number of organs for transplan-
tation. Living donor liver transplantation
should also be considered for patients with
HCC in groups in which time on the waiting
list is more than 7 months (39). The use of an
“expanded” criterion for living donor liver
transplantation in HCC has been discussed.
This criterion is based on the following fea-
tures (39): single tumor <7 cm or up to 3
nodules, none >5 cm or up to 5 nodules,
none >3 cm or a partial response to any of the
treatments fulfilling standard criteria. How-
ever, these criteria still need validation and
should not be used in routine clinical prac-
tice.
Immunosuppressive agents such as cy-
closporine and tacrolimus are known to be
stimulators of hepatic regeneration. How-
ever, their interference with tumor progres-
sion is still a matter of controversy.
Percutaneous treatment
Several types of percutaneous treatment
are available for HCC, all of them aiming at
destruction of the tumor with a safety margin
of non-tumoral liver. The techniques most
commonly used are alcoholization and
radiofrequency. However, substances such
as boiling saline solution and acetic acid can
also be used. Coagulation by radiofrequency,
microwaves, laser therapy, and electrocau-
terization are percutaneous techniques used
for the treatment of HCC. Percutaneous etha-
nol injection (PEI) is the technique for which
most experience has been obtained, with
various studies showing its efficacy.
Absolute alcohol causes cell dehydration
and extensive coagulative cell necrosis in
addition to leading to thrombosis of the
intratumoral vessels. PEI is a procedure of
easy execution, good tolerability and low
cost, which can be applied during repeated
sessions (48,49). Using ultrasound, the alco-
holization needle is introduced until it reaches
the nodule. A 22-G needle or a needle with
specific side perforations for the procedure
is used. After reaching the tumor, always
under US visualization, the injection of ab-
solute alcohol is started. The amount of alco-
hol injected per session depends on tumor
size and tolerability on the part of the pa-
tient, ranging from 1 to 10 ml, with an aver-
age of 5 ml per session. Larger volumes are
inadvisable because of the risk of the occur-
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rence of an extensive area of hepatic necro-
sis. However, injection of a large volume of
alcohol in a single session without the occur-
rence of marked side effects has been re-
ported in the literature. The number of alco-
holization sessions depends on the size and
consistency of the tumor and on the distribu-
tion of alcohol through the tumor. The final
objective of this treatment is to obtain total
HCC necrosis.
Serious complications are rare. Pain dur-
ing the procedure is common and is related
to alcohol reflux towards the hepatic capsule
or to alcohol escape through the portal vein,
visualized by US during the procedure. In
our routine we do not use sedation or sys-
temic analgesia before PEI. There have been
reports of hemoperitoneum, pleurisy, hemo-
bilia, hepatic abscess, cholangitis, and he-
patic decompensation (50). Portal thrombo-
sis may also occur after PEI as a conse-
quence of vascular invasion by the tumor or
of chemical thrombosis caused by alcohol.
Differentiation of these events can be ob-
tained using US-Doppler or FNAB of the
thrombus (14).
A single tumor smaller than 3 cm or up to
three nodules, none of them larger than 3 cm,
without extrahepatic metastases and with
only slightly deteriorated hepatic functional
reserve (Child-Pugh A and B) and without
surgical indication (34,37,48) are the major
indications for PEI.
The therapeutic efficacy of PEI depends
on various factors. Vilana et al. (49), in an
analysis of alcoholization of tumors measur-
ing less than 5 cm, observed that tumors
smaller than 3 cm gave a better response and
concluded that the success of PEI is related
to tumor size at the beginning of treatment,
as also reported by others. PEI may have a
therapeutic efficacy similar to resection or
even to liver transplantation, especially when
patients with poor hepatic function are se-
lected for surgical treatment (48).
Local recurrence is observed in 17% of
cases. The appearance of new lesions after
treatment may reach 60% at 2 years and 80%
at 5 years and is related to tumor size, inad-
equate necrosis, presence of pretreatment
intrahepatic metastases, or even to the ap-
pearance of metachronic lesions during pa-
tient follow-up (49,50).
Depending on the degree of hepatic dys-
function, the survival of patients submitted
to PEI may reach 85% in the first year, 60%
in the third, and 30% in the fifth, rates simi-
lar to those obtained with surgical resection
(34,37,48,50).
Radiofrequency has also been used suc-
cessfully for patients with HCC. The indica-
tions are similar to those for PEI (51). No
randomized studies comparing the two per-
cutaneous techniques in terms of antitumoral
effect and patient survival are available. The
advantage of radiofrequency over PEI is the
smaller number of sessions needed to obtain
tumor necrosis. However, PEI is less expen-
sive and is easy to perform, requiring no
hospitalization. Radiofrequency should be
avoided in superficial lesions because of the
risk of tumoral dissemination through the
path of the needle. The 5-year survival rate
for patients submitted to radiofrequency is
about 33% (52). The option for PEI and
radiofrequency depends on the experience
of each group.
Transarterial embolization or
chemoembolization
Since HCC is a tumor predominantly
irrigated by the arterial system of the liver,
blockade of the blood supply to the tumor is
used as treatment. The surgical route has
been abandoned due to its severe side effects
and has been replaced with the use of arterial
obstruction by a peripheral route using inter-
ventionist radiology. Tumors that cannot be
submitted to radical treatment are consid-
ered for transarterial embolization (TAE)/
chemoembolization (TACE). Usually, pa-
tients with multiple diffuse tumors or single
tumors larger than 5 cm, with barely deterio-
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rated hepatic function are the main candi-
dates for treatment by TAE (28).
Using fluoroscopy, the tumor nourishing
artery is located and selective obstruction
with gelatin particles or preformed polyvinyl
microparticles is started after advancing the
catheter as close as possible to the HCC.
This procedure may be combined with the
use of chemotherapeutic agents such as doxo-
rubicin, epirubicin, mitomycin, or cisplatin
in combination or not with lipiodol, a sub-
stance retained by neoplastic cells. These
combinations seem to improve the antitu-
moral effect, although in most cases they do
not improve patient survival (53).
In a recent study, Llovet et al. (54) dem-
onstrated improved survival of patients sub-
mitted to TACE compared to control pa-
tients (no antitumoral treatment). Patients
with multinodular HCC and asymptomatic
with respect to the tumor, without vascular
invasion or distant metastases, with preserved
hepatic function (preferentially Child-Pugh
A) and not considered to be candidates for
liver transplantation may benefit from TACE.
Thrombosis of the portal vein and hepa-
tofugal portal flow are considered to be a
contraindication of TAE due to the risk of
severe hepatic insufficiency after the proce-
dure. The post-embolization syndrome, char-
acterized by fever, abdominal pain, nausea
and vomiting, and frequently self-limited, is
observed in most patients submitted to TAE
or TACE. Fifteen to 30% of the patients may
present severe symptoms such as gallblad-
der infarction by embolization of the cystic
artery, arteritis, thrombosis of the intima
layer of the hepatic artery, pulmonary edema,
pancreatitis, or even hepatic insufficiency
due to poor hepatic function. For this reason,
this therapeutic modality is avoided in Child-
Pugh C patients (53,55). A higher frequency
of post-embolization syndrome and of gas-
trointestinal toxicity tends to occur in cases
in which lipiodol is used as the chemothera-
peutic vehicle. Antibiotic prophylaxis should
not be routinely applied to patients submit-
ted to TAE (56).
TAE can reduce the size of the tumor,
leading to ischemic necrosis of more than
80% of the HCC, while the cells that infil-
trate the tumoral capsule and the portal vein
continue to be viable. Relapses are also fre-
quent. In cases of relapse or persistence of
viable cells, the procedure can be repeated or
post-TAE PEI can be performed (55). How-
ever, the probability of maintenance of this
level of therapeutic response is about 10% at
2 years. Larger tumors tend to respond to
TAE at higher frequency, probably due to
the hypervascularization of larger HCC (53).
Both TAE and TACE should be periodically
repeated. The time interval has not been
defined, but the suggestion is to repeat the
procedure every 3 to 6 months.
Patients with a single tumor larger than 3
cm that cannot be treated surgically may
benefit from the combination of TAE and
PEI. The combination of these two therapeu-
tic techniques is based on the persistence of
viable neoplastic cells after TAE, especially
at the periphery of the lesion, where the
predominant circulation seems to be the
venous one (47). In addition, large tumors
require larger amounts of alcohol to be ne-
crotized. Thus, when TAE is performed first,
necrosis of the central part of the HCC is
obtained, and PEI is later performed at the
periphery. This combination of techniques
seems to be effective in reducing tumor size
and increasing patient survival (57,58).
TACE has been used as co-adjuvant treat-
ment when the patient is on the waiting list
for liver transplantation (46). In our experi-
ence, the combination of TAE and PEI has
shown a good antitumoral effect in patients
who are on the waiting list for liver trans-
plantation (47).
However, the possibility of tumor dis-
semination after treatment, detected by the
presence of messenger RNA for AFP (58)
and by a higher incidence of pulmonary
metastases after TAE, should be considered
at the time when a decision has to be made
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about co-adjuvant treatment in addition to
radical therapy.
Evaluation of the therapeutic
response
The therapeutic response to percutaneous
methods (PEI and radiofrequency) and to TAE
is determined by using CT in the arterial phase,
at least 1 month after the procedure. Before
this period, areas suspected of tumor viability
may be detected, corresponding to areas of
peritumoral edema caused by the therapeutic
procedure. The persistence of a hyperdense
image in the arterial phase is suggestive of
tumor viability. The absence of contrast up-
take is indicative of tumor necrosis. In MR, the
loss of signal intensity in potentiated sequences
in T2 and after the administration of paramag-
netic contrast in potentiated sequences in T1 is
also suggestive of tumor necrosis. US-Dop-
pler has been used for the control of treatment
with satisfactory results. The presence of an
intratumoral pulsatile flow indicates the per-
sistence of viable tumor cells. However, the
absence of a Doppler signal does not rule out
the possibility of tumor viability.
A quarterly US, measurement of serum
AFP and dynamic CT at 6- to 8-month inter-
vals are suggested for post-treatment follow-
up. The absence of an increase in the lesion,
in AFP levels or in contrast uptake by CT is
indicative of successful treatment. The World
Health Organization adopts the following
criteria for response to treatment (59):
Complete response: complete disappear-
ance of known lesions and no occurrence of
new lesions as evaluated during two obser-
vations separated by an interval of at least 4
weeks.
Partial response: reduction of the tumor
mass ≥50% as evaluated during two obser-
vations separated by an interval of at least 4
weeks.
Stable disease: not classified as complete
response, partial response or progressive dis-
ease
Progressive disease: an increase ≥25% in
the tumoral mass of one or more known
lesions or appearance of new lesions.
Serum AFP levels can be used as a pa-
rameter of response to treatment only in
cases in which their levels were elevated
before the procedure. Elevation of their lev-
els after treatment is suggestive of tumor
recurrence.
Other therapies
In HCC, both estrogen and androgen re-
ceptors can be found on the membrane of
neoplastic cells, theoretically justifying hor-
monal therapy for this type of neoplasia. The
use of antiestrogens has been suggested for
the treatment of HCC. However, tamoxifen,
a non-steroid antiestrogen, did not prove to
be useful in improving the quality of life of
patients with HCC even when administered
at high doses (60).
Radiotherapy, systemic chemotherapy
and the use of interferon have not shown
satisfactory results in terms of antitumoral
effect or survival of patients with HCC (14).
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